BRPI0821211A2 - Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo. - Google Patents

Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.

Info

Publication number
BRPI0821211A2
BRPI0821211A2 BRPI0821211-2A BRPI0821211A BRPI0821211A2 BR PI0821211 A2 BRPI0821211 A2 BR PI0821211A2 BR PI0821211 A BRPI0821211 A BR PI0821211A BR PI0821211 A2 BRPI0821211 A2 BR PI0821211A2
Authority
BR
Brazil
Prior art keywords
humanized
preparation
human antibody
antibody
human
Prior art date
Application number
BRPI0821211-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Guo
Yajun
Qian
Weizhu
Hou
Sheng
Li
Bohua
Wang
Hão
Ma
Jing
Original Assignee
Shanghai Guojian Bio Tech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200710094456 external-priority patent/CN101245108B/zh
Application filed by Shanghai Guojian Bio Tech Inst filed Critical Shanghai Guojian Bio Tech Inst
Publication of BRPI0821211A2 publication Critical patent/BRPI0821211A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BRPI0821211-2A 2007-12-13 2008-12-03 Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo. BRPI0821211A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN 200710094456 CN101245108B (zh) 2007-12-13 2007-12-13 抗人cd34抗体、其制备方法及用途
CN200810043016 2008-01-08
PCT/CN2008/001963 WO2009079922A1 (en) 2007-12-13 2008-12-03 Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0821211A2 true BRPI0821211A2 (pt) 2015-06-16

Family

ID=40800709

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821211-2A BRPI0821211A2 (pt) 2007-12-13 2008-12-03 Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.

Country Status (6)

Country Link
US (1) US20100311955A1 (enExample)
EP (1) EP2233501B1 (enExample)
JP (1) JP2011505810A (enExample)
BR (1) BRPI0821211A2 (enExample)
CA (1) CA2708407A1 (enExample)
WO (1) WO2009079922A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
TWI443107B (zh) 2011-12-29 2014-07-01 Ind Tech Res Inst 人源化之抗人類細胞表面抗原ｃｄ３４之單株抗體及其應用
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US10604586B2 (en) * 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
CN109265547B (zh) * 2018-07-23 2022-07-26 中国科学院微生物研究所 一种抗cd47抗体及其应用
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
CN118501458B (zh) * 2024-05-08 2025-09-30 广东省第二人民医院（广东省卫生应急医院） 一种外周血细胞外囊泡表面多种免疫标志物联合检测的试剂盒及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH11332578A (ja) * 1998-05-25 1999-12-07 Asahi Chem Ind Co Ltd 細胞の分離装置及び分離方法
JPH11332594A (ja) * 1998-05-26 1999-12-07 Asahi Chem Ind Co Ltd Ｃｄ４陽性細胞の分離装置および分離方法
CN1307640A (zh) * 1998-05-25 2001-08-08 旭化成株式会社 细胞分离装置和分离方法
ATE382633T1 (de) * 2000-05-23 2008-01-15 Baxter Healthcare Sa Reagenzien zur zellselektion und verfahren zur anwendung
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CN101245108B (zh) * 2007-12-13 2013-04-10 上海抗体药物国家工程研究中心有限公司 抗人cd34抗体、其制备方法及用途

Also Published As

Publication number Publication date
EP2233501A4 (en) 2010-12-01
JP2011505810A (ja) 2011-03-03
EP2233501B1 (en) 2012-07-11
WO2009079922A1 (en) 2009-07-02
EP2233501A1 (en) 2010-09-29
CA2708407A1 (en) 2009-07-02
US20100311955A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
BRPI0821211A2 (pt) Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
IL273607A (en) Humanized antibodies against liv-1, preparations containing them and their uses
BRPI0815983A2 (pt) anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
HRP20181218T1 (hr) Humanizirana anti-il-6 protutijela, pripravci, postupci pripreme i upotrebe
BRPI0917370A2 (pt) anticorpos anti-il-13 manipulados, composições, métodos e usos.
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
BRPI0812005A2 (pt) anticorpos humanizados para o globulômeros de ab(20-42) e seus usos.
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
NL1032452A1 (nl) Menselijke monoklonale antilichamen tegen activine receptor-achtig kinase-1.
NO344963B1 (no) Humanisert antistoff
DK2019840T3 (da) Antagonist anti-human CD40 monoklonalt antistof.
BRPI0820298A8 (pt) composições e métodos de anticorpos anti-vegf
IL205127A (en) Antibody to aβ is humanized, a preparation containing it and its uses
CU24058B1 (es) Antagonistas de pcsk9
IL197928A (en) A monoclonal antibody munched on steap-1, its immunoconjugates its uses
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0916915A2 (pt) anticorpos anti-il-17a/f de reatividade cruzada e biespecíficos
WO2015010100A3 (en) Humanized antibodies with ultralong complementarity determining regions
BRPI0818865A2 (pt) Anticorpos monoclonais contra proteína c ativada.
BRPI0814644A2 (pt) Anticorpos para cd200 e usos destes na inibição de respostas imunes.
HK1198328A1 (zh) 使用抗il-13抗體治療哮喘的方法和組合物
BRPI0810826A2 (pt) epítopos funcionais de osteopontina, anticorpo monoclonal contra os epítopos e usos dos mesmos.
BRPI0922288A2 (pt) anticorpos monoclonais anti-ferroportina 1 e seus usos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. PAGAR RESTAURACAO.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.